Skip Navigation

Rheumatology 2008 47(Supplement 4):iv20-iv22; doi:10.1093/rheumatology/ken166
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roux, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Roux, C.
Related Collections
Right arrow Osteoporosis and Metabolic Bone Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article appears in the following Rheumatology issue: Management of Osteoporosis: A Physiological Answer for a Living Tissue. Proceedings of a satellite symposium held on the occasion of the EULAR Congress, Paris, France, June 13, 2008. The symposium and these proceedings were made possible by an unrestricted educational grant from Servier [View the issue table of contents]

Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis

C. Roux

Rheumatology Department, Paris Descartes University, Cochin Hospital, Paris, France.

Correspondence to: C. Roux, Rheumatology Department, Paris Descartes University, Cochin Hospital, Paris, France. E-mail: christian.roux{at}cch.ap-hop-paris.fr


  Abstract

Strontium ranelate is a bone-seeking element that has been assessed in post-menopausal osteoporosis in two large double-blind, placebo-controlled studies. This treatment is able to decrease the risk of vertebral fractures, by 41% over 3 yrs, and by 49% within the first year of treatment. This risk of non-vertebral fractures is decreased by 16% and, in patients at high risk for such a fracture, the risk of hip fracture is decreased by 36% over 3 yrs. Recent 5-yr data from these double-blind, placebo-controlled studies show that the anti-fracture efficacy is maintained over time. Treatment efficacy with strontium ranelate has been documented across a wide range of patient profiles: age, number of prevalent vertebral fractures, BMI, as well as family history of osteoporosis and addiction to smoking are not determinants of anti-fracture efficacy. During these clinical trials, safety was good. Its large spectrum of efficacy allows the use of strontium ranelate in the different subgroups of patients with post-menopausal osteoporosis.

KEY WORDS: Osteoporosis, Vertebral fracture, Non-vertebral fracture, Strontium ranelate, Anti-fracture efficacy

Submitted 31 January 2008; revised version accepted 1 April 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Ferrari
Continuous broad protection against osteoporotic fractures with strontium ranelate
Rheumatology, October 1, 2009; 48(suppl_4): iv20 - iv24.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.